TICKERNERD
Menu
WSTWSTHealthcare · Medical Instruments & Supplies

WST Stock Forecast: West Pharmaceutical Services, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$377
+3.23% on the day

The 17 Wall Street analysts covering West Pharmaceutical Services, Inc. hold a median 12-month price target of $410 — +8.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 3 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$25.7B
Ticker Nerd rank
94 / 100
Median analyst target
$410
Analysts covering
17
Revenue$872.3M+13.8% y/y
Operating income$191.9M
Net income$154.0M
Free cash flow$80.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.3%
1M
+10.8%
YTD
+37.3%
1Y
+38.7%
From 52W high
0.0%
From 52W low
+63.4%
$231
$377
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

WST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores West Pharmaceutical Services, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
96
Momentum
93
Volatility
90
Value
80
Quality
77
Issuance
74
Growth
72
Accruals
38
Size
8

Revisions (96): Analysts have, on balance, been raising their forecasts.

Accruals (38): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

WST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300$350$400$450Jan 26Apr 26Jul 26Oct 26WSTHigh $459Median $410Low $340

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
16 Buy1 Hold0 Sell
Low $340Median $410High $459

The green dot is the last close — the median target sits +8.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
22 Sept 2026Morgan StanleyUpgradeOverweight$365 → $400
9 Sept 2026UBSMaintainsBuy$340 → $415
9 Sept 2026UBSMaintainsBuy—
3 Aug 2026CitigroupMaintainsBuy$400 → $412
3 Aug 2026CitigroupMaintainsBuy—
27 July 2026Evercore ISI GroupMaintainsOutperform$410 → $425
27 July 2026Evercore ISI GroupMaintainsOutperform—
13 July 2026BNP ParibasInitiatesOutperform$447
13 July 2026BNP ParibasInitiatesOutperform—
9 July 2026Morgan StanleyMaintainsEqual-Weight$325 → $365
9 July 2026Morgan StanleyMaintainsEqual-Weight—
6 July 2026Evercore ISI GroupMaintainsOutperform$390 → $410
6 July 2026Evercore ISI GroupMaintainsOutperform—
2 July 2026KeybancMaintainsOverweight—
9 June 2026BarclaysUpgradeOverweight—
2 June 2026Stephens & Co.ReiteratesOverweight—
2 June 2026Wolfe ResearchAssumesOutperform—
29 May 2026Morgan StanleyMaintainsEqual-Weight—
27 Apr 2026BarclaysMaintainsEqual-Weight—
14 Apr 2026BarclaysMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

WST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, West Pharmaceutical Services, Inc. returned +38.7% against +16.2% for the S&P 500, dividends included.

WST vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Jan 26Apr 26Jul 26Oct 26WSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

WST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.1%
Analysts raising
14
Analysts cutting
0
Fundamentals

West Pharmaceutical Services, Inc. (WST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
46.8×

Cheaper than 15% of US stocks

Price / sales
7.7×

Cheaper than 17% of US stocks

Price / book
8.6×

Cheaper than 11% of US stocks

EV / EBITDA
28.0×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
13.8%

Higher than 60% of US stocks

Earnings growth (YoY)
16.8%

Higher than 55% of US stocks

Gross margin
37.7%

Higher than 46% of US stocks

Operating margin
22.5%

Higher than 82% of US stocks

Net margin
17.0%

Higher than 80% of US stocks

Returns & dividend
Return on equity
19.1%

Higher than 80% of US stocks

Return on assets
11.4%

Higher than 94% of US stocks

Dividend yield
0.2%

Higher than 41% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

West Pharmaceutical Services, Inc. (WST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • West Pharmaceutical Services, Inc. has a market value of $25.7B and an enterprise value of $25.6B.

  • Revenue in the twelve months to 30 June 2026: $3.3B. The latest quarter grew 13.8% year on year.

  • Net income over the same four quarters: $564.9M, a 17.0% net margin.

  • Diluted earnings per share, trailing twelve months: $7.81.

  • Free cash flow in the twelve months to 30 June 2026: $436.9M, after $225.3M of capital spending.

  • West Pharmaceutical Services, Inc. spent $457.1M on share buybacks and $62.4M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 70.4M.

  • Trailing P/E: 46.8×; forward P/E: 36.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.24%, paying out 11% of earnings.

  • West Pharmaceutical Services, Inc. employs 10,800 people — $308K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Oct 2026

Data provided by Twelve Data

Peers

WST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
WSTWest Pharmaceutical Services, Inc.$25.7B
94
ALCAlcon AG$31.8B
68
RMDResMed, Inc.$32.0B
72
SOLVSolventum Corp.$15.2B
92
MDLNMedline, Inc.$46.8B
19
BDXBecton, Dickinson & Co.$48.7B
93
BAXBaxter International, Inc.$12.1B
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own West Pharmaceutical Services, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WST news & analysis

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

Zacks Investment Research · 18 Sept 2026positive

Zacks highlighted West Pharmaceutical's exposure to biologics, its Annex 1 projects, and growth in delivery devices as factors supporting its prospects, while acknowledging near-term headwinds. The article framed these strengths as reasons to consider adding the stock to a portfolio.

Why it matters — WST watchers would care because the piece points to the company's biologics exposure, Annex 1 initiatives, and delivery-device momentum as supportive drivers despite current challenges.

West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

West Pharmaceutical Services, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item reports on the company's participation in the conference.

Why it matters — A WST watcher would care because the conference presentation and transcript may offer insight into the company's outlook and strategy as shared with investors.

West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

West Pharmaceutical Services, Inc. presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of its presentation published. The appearance provided a forum for the company to discuss its business at the industry event.

Why it matters — A WST watcher would want to follow the presentation transcript for insights into how management addressed the company's operations and outlook before an investor audience.

West to Participate in Upcoming Investor Conferences

PRNewsWire · 26 Aug 2026neutral

West Pharmaceutical Services announced it will present at the Wells Fargo Annual Healthcare Conference on September 10, 2026, in Everett, MA, and the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026.

Why it matters — A WST watcher would care because the company's participation at these investor conferences offers management an opportunity to communicate with investors in a public setting.

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

Zacks Investment Research · 14 Aug 2026positive

West Pharmaceutical Services stock has surged 38.1% since the end of March. The rally is attributed to higher demand for high-value products (HVP), growth related to GLP-1 products, and productivity gains.

Why it matters — For WST watchers, this highlights the key demand drivers behind the company's recent stock performance and operational momentum.

FAQ

Frequently asked questions about WST stock

What is the WST stock price forecast for 2026-2027?

The 17 Wall Street analysts covering West Pharmaceutical Services, Inc. have a median 12-month price target of $410, with estimates ranging from $340 to $459. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WST stock a buy right now?

Of the 17 analysts covering West Pharmaceutical Services, Inc., 16 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks West Pharmaceutical Services, Inc. 94 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WST?

As at 3 Oct 2026, West Pharmaceutical Services, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).

Will WST stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +8.8% from the last close, and Ticker Nerd's factor model ranks West Pharmaceutical Services, Inc. 94 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WST stock forecast for 2030?

No analyst covering West Pharmaceutical Services, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $340 to $459 over the next 12 months.

How has WST stock performed over the past year?

West Pharmaceutical Services, Inc. returned +38.7% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does West Pharmaceutical Services, Inc. do?

West Pharmaceutical Services Inc. is a healthcare products manufacturer focused on the design, development, and production of containment and delivery systems for injectable drugs and other healthcare products.

What is the latest news on WST?

The most recent item we track (Zacks Investment Research, 18 Sept 2026): "Reasons to Add West Pharmaceutical Stock to Your Portfolio Now". Zacks highlighted West Pharmaceutical's exposure to biologics, its Annex 1 projects, and growth in delivery devices as factors supporting its prospects, while acknowledging near-term headwinds. The article framed these strengths as reasons to consider adding the stock to a portfolio.

Company

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services Inc. is a healthcare products manufacturer focused on the design, development, and production of containment and delivery systems for injectable drugs and other healthcare products. The company supplies critical components such as stoppers, seals, syringe and cartridge parts, reconstitution and transfer systems, safety and administration devices, and advanced injection solutions that support the packaging and delivery of pharmaceuticals and biologics. It also provides contract manufacturing and analytical lab services through its proprietary and contract-manufactured product segments. West Pharmaceutical Services Inc. serves a broad customer base that includes pharmaceutical, biotechnology, generic-drug, medical device, and consumer healthcare companies. Headquartered in Exton, Pennsylvania, the company plays an important role in the healthcare supply chain by helping enable safe, reliable, and efficient delivery of injectable therapies worldwide.

CEO Mr. Michel Lagarde · 10,800 employees · United States · https://www.westpharma.com